Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015

This article was originally published in PharmAsia News

Executive Summary

AHMEDABAD, India - In a few months India's Zydus Cadila will join a handful of elite Indian companies like Dr. Reddy's and Cipla that managed to surpass the magic $1 billion mark in annual sales. Cadila says it has a comprehensive blueprint ready to cruise to $3 billion by 2015

You may also be interested in...



Cadila Healthcare Chairman Pankaj Patel On The Potential For Consolidation In The Indian Industry: An Interview With PharmAsia News

Every player wants to continue to work rather than take a back seat. Unless that mindset comes to India, consolidation within Indian players is tough to find, says Patel.

Cadila Healthcare Chairman Pankaj Patel On The Potential For Consolidation In The Indian Industry: An Interview With PharmAsia News

Every player wants to continue to work rather than take a back seat. Unless that mindset comes to India, consolidation within Indian players is tough to find, says Patel.

Cadila Heathcare Chairman Pankaj Patel On Consolidation In The Indian Industry And Why It's Not Happening Locally: An Interview With PharmAsia News

Pankaj Patel, chairman and managing director of India's fifth-largest firm Cadila Healthcare expresses an unswerving support for growth through partnerships. Riding on an early partnership with Swiss firm Nycomed and lucrative opportunities in niche segments like vaccines, Cadila's growth has been extraordinary - 18-fold growth in the last 15 years.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel